FT819 clinical trials
FT819 is named as an intervention in 3 current clinical trials in our USA, UK, France and Sweden registers. 2 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Fate Therapeutics. The most-studied condition is Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV).
Patient leaflets for FT819
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of FT819
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862 · ClinicalTrials.gov ↗ · Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus
|
Phase 2 | Recruiting | Fate Therapeutics | USA |
|
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)
|
Phase 1 | Recruiting | Fate Therapeutics | UK, USA, France, Sweden |
|
FT819 in Subjects With B-cell Malignancies
NCT04629729 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
|
Phase 1 | Active, closed | Fate Therapeutics | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with FT819
11 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Fate Therapeutics | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Sweden | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about FT819 trials
How many clinical trials are testing FT819?
3 current trials in our USA, UK, France and Sweden registers name FT819 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are FT819 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 1 with sites in UK, 1 with sites in France and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors FT819 clinical trials?
The lead sponsor is Fate Therapeutics. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how FT819 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how FT819 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists FT819 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.